By Deena Beasley Oct 7 (Reuters) – Novartis’ experimental del-desiran for a rare type of muscular dystrophy was expected to be a winner, with the Swiss company's CEO predicting annual peak sales of $5
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Shikshagraha’s Mothers of Courage Named Finalist at UN SDG Action Awards 2026
From Bihar’s villages to Rome, Mothers of Courage among the finalists at the UN SDG…
Arsenal manager Mikel Arteta extends contract until 2030
VIDEO SHOWS: ARCHIVE SHOTS OF ARSENAL MANAGER MIKEL ARTETA / STILLS OF ARTETA WITH PREMIER…
Arrest warrant issued against former German top spy, Focus outlet says
KARLSRUHE, Germany, Oct 7 (Reuters) - A judge of Germany's Federal Court of Justice on…
